Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$1.78M$1.78M+26.3% vs Q1 2020 Net Income-$28.75M-$28.75MN/M vs Q1 2020 EPS Diluted-$0.57-$0.57N/M vs Q1 2020 Operating Income-$28,529,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1605.5%−503.4 pt vs Q1 2020
Net margin-1618.1%−510.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 7, 2021 · 37 d after period end